MISSISSAUGA, ON, April 23, 2024 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on March 13, 2024, Health Canada issued marketing authorization for Tecentriq® SC ...

Sanofi SA (NASDAQ: SNY) has announced new study data of Soliqua 100/33 (insulin glargine and lixisenatide injection) that met its two primary endpoints and all key secondary endpoints in a head-to ...

The FINANCIAL — Sanofi announced on January 4 that Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) is now available by prescription in U.S. pharmacies. Soliqua ...

Paris, France - January 4, 2017 - Sanofi announced today that Soliqua (TM) 100/33 (insulin glargine 100 Units/mL & lixisenatide * 33 mcg/mL injection) is now available by prescription in U.S ...